Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Crisp Therapeutics received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy in the world. Crispr shares were up close to 5% on the news. Don’t miss this list of 3 high-yield ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...